---
title: "\"YuanSi ShengTai\" completes Series B financing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281095552.md"
description: "\"YuanSi ShengTai\" has completed its Series B financing, led by an international biotechnology fund, with Decheng Capital and Dinghui VGC co-leading, and followed by the Abu Dhabi Investment Authority, Temasek, Qiming Venture Partners, and others. Existing shareholders, including AstraZeneca, continue to increase their holdings. The financing will be used to deepen the intelligent iteration of the macrocyclic peptide discovery platform Synova™ and accelerate the transition of the innovative drug pipeline to the clinical stage"
datetime: "2026-03-31T00:44:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281095552.md)
  - [en](https://longbridge.com/en/news/281095552.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281095552.md)
generator: "portal-rs"
---

# "YuanSi ShengTai" completes Series B financing

36Kr learned that "YuanSi ShengTai" announced the completion of its Series B financing. It was led by an international biotechnology fund, with co-leads from Decheng Capital and Dinghui VGC, along with follow-on investments from a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), Temasek's wholly-owned subsidiary Dama Capital, Qiming Venture Partners, Boyuan Capital, and other well-known industry investment institutions. Meanwhile, existing shareholders such as AstraZeneca, Eli Lilly Asia Fund, Innovation Works, Wuyuan Capital, Hillhouse Ventures (GL Ventures), Biotech Development Fund, and Lenovo Capital continue to increase their stakes. The funds will be primarily used to deepen the intelligent iteration of its self-developed macrocyclic peptide discovery platform Synova™ and accelerate the conversion of the company's diversified innovative drug pipeline into clinical stages

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [300685.CN](https://longbridge.com/en/quote/300685.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159938.CN](https://longbridge.com/en/quote/159938.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [PJP.US](https://longbridge.com/en/quote/PJP.US.md)
- [XPH.US](https://longbridge.com/en/quote/XPH.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [PPH.US](https://longbridge.com/en/quote/PPH.US.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)

## Related News & Research

- [Goldman Sachs Sticks to Their Buy Rating for AstraZeneca (AZN)](https://longbridge.com/en/news/296444477.md)
- [AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies](https://longbridge.com/en/news/296114723.md)
- [AstraZeneca halts lung cancer trial of volrustomig in latest blow to pipeline](https://longbridge.com/en/news/296069146.md)
- [AstraZeneca: Tagrisso Plus Orpathys Phase III Trial Shows PFS, OS Improvements In EGFRm Lung Cancer](https://longbridge.com/en/news/296071807.md)
- [Astrazeneca Plc (NYSE:AZN) Given Consensus Rating of "Moderate Buy" by Analysts](https://longbridge.com/en/news/296693781.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**